Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843051 | 0.96 | NSD2 (0.56) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1755275 | 0.94 | NSD2 (0.57) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1707567 | 0.91 | NSD2 (0.56) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1708530 | 0.90 | NSD2 (0.55) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1839128 | 0.89 | NSD2 (0.46) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1707490 | 0.87 | NSD2 (0.54) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL13536785 | 0.85 | NSD2 (0.45) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1842342 | 0.85 | NSD2 (0.45) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1708497 | 0.85 | NSD2 (0.49) | NSD2IRAK4LMNAUSP2CYP1A2 | |
| SCHEMBL1839570 | 0.85 | EGFR (0.51) | LMNALRRK2RETEGFRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841311-B2 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8841311-B2 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8841311-B2 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| EP-2321284-B1 | SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Bayer Pharma AG (DE) | 2012-05-09 | — | — | EP | disclosed |
| EP-2321284-B1 | SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Bayer Pharma AG (DE) | 2012-05-09 | — | — | EP | disclosed |
| US-20110166168-A1 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166168-A1 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166168-A1 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| EP-2321284-A1 | SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010009845-A1 | SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010009845-A1 | SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166168-A1 | Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | TPMT, IFNG, HLA-DRB1 | NSD2 1335/4885IRAK4 239/4885LMNA 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.